SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that two data sets from the Company’s Phase 3 VANISH Program evaluating ibrexafungerp as a treatment for vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, were accepted for poster presentations at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting, to be held virtually from April 30 – May 2, 2021.
Brexafemme, the expected trade name for ibrexafungerp, is a one-day oral antifungal treatment for VVC under regulatory review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date set for June 1, 2021.
Title: Phase 3 Oral Ibrexafungerp Study in Vulvovaginal Candidiasis (VANISH-303):
Outcomes in Non-albicans Candida spp.
Poster #: ID961398 Authors: Dr. Nkechi Azie, Dr. David Angulo, Dr. Paul Nyirjesy
Title: Efficacy and Safety of Oral Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis: A Phase 3 Study (VANISH-306)
Poster # ID957079
Authors: Dr. Nkechi Azie, Dr. David Angulo, Dr. Ryan Sobel
All posters will be live via the ACOG virtual meeting platform starting April 30th at 11 am ET. Register to attend via Link. The posters will be made be available for three months and can be found on the SCYNEXIS website at https://www.scynexis.com/news-media/events.